Efficacy observation of carilizumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer
10.3760/cma.j.cn115355-20240911-00431
- VernacularTitle:卡瑞利珠单抗联合同步放化疗治疗局部晚期子宫颈癌效果观察
- Author:
Jia LI
1
;
Yifei LI
1
Author Information
1. 山西省肿瘤医院 中国医学科学院肿瘤医院山西医院 山西医科大学附属肿瘤医院放射治疗科，太原 030013
- Publication Type:Journal Article
- Keywords:
Uterine cervical neoplasms;
Chemotherapy;
Radiotherapy;
Carilizumab
- From:
Cancer Research and Clinic
2025;37(7):525-529
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the therapeutic effect of carilizumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.Methods:A retrospective case-control study was conducted. The clinical data of 70 patients with locally advanced cervical cancer admitted to Shanxi Province Cancer Hospital from July 2020 to July 2021 were collected. According to the treatment method, all patients were divided into the control group (chemoradiotherapy alone group, 36 cases) and the observation group (carilizumab combined with concurrent chemoradiotherapy group, 34 cases). The short-term efficacy, serum tumor markers level, T cell subsets, adverse reactions, and progression-free survival (PFS) of the 2 groups were compared.Results:The disease control rate in the observation group was higher than that in the control group [94.12% (32/34) vs. 75.00% (27/36)], and the difference was statistically significant ( χ2 = 4.83, P < 0.05). The levels of serum carcinoma embryonic antigen (CEA), carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen(SCC-Ag), human epididymis protein 4 (HE4), vascular endothelial growth factor A (VEGF-A), and vascular endothelial growth factor receptor 2 (VEGFR2) of the both groups after treatment for 180 d were lower than those of the same corresponding group the day before treatment (all P < 0.05). The levels of serum CEA, CA125, SCC-Ag, HE4, VEGF-A and VEGFR2 after treatment for 180 d in the observation group were lower than those in the control group (all P < 0.05). The proportions of serum CD3 + T cells, CD4 + T cells of the both groups after treatment for 180 d were higher than those of the same corresponding group the day before treatment, and the proportion of CD8 + T cells after treatment for 180 d was lower than that the day before treatment (all P < 0.05). The proportions of serum CD3 + T cells and CD4 + T cells after treatment for 180 d in the observation group were higher than those in the control group, and the proportion of CD8 + T cells in the observation group was lower than that in the control group (all P < 0.05). There were no statistically significant differences in the incidence of bone marrow suppression, gastrointestinal reactions, radiation cystitis and radiation proctitis between the observation group and the control group (all P > 0.05). The median follow-up time was 17 (2-24) months. The 1-year PFS rates of the observation group and the control group were 100.00%, 79.17%, respectively, and the difference in the PFS was statistically significant ( P < 0.001). Conclusions:The combination of carilizumab and concurrent chemoradiotherapy is effective in the treatment of locally advanced cervical cancer. It can decrease serum tumor marker levels, regulate T cell subsets. No serious adverse reactions are found.
